PMID- 38523640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 15
DP  - 2024
TI  - Anti-diabetic and anti-inflammatory bioactive hits from Coriaria intermedia 
      Matsum. stem and Dracontomelon dao (Blanco) Merr. & Rolfe bark through 
      bioassay-guided fractionation and liquid chromatography-tandem mass spectrometry.
PG  - 1349725
LID - 10.3389/fphar.2024.1349725 [doi]
LID - 1349725
AB  - Women have been found to be at a higher risk of morbidity and mortality from type 
      2 diabetes mellitus (T2DM) and asthma. alpha-Glucosidase inhibitors have been used to 
      treat T2DM, and arachidonic acid 15-lipoxygenase (ALOX15) inhibitors have been 
      suggested to be used as treatments for asthma and T2DM. Compounds that inhibit 
      both enzymes may be studied as potential treatments for people with both T2DM and 
      asthma. This study aimed to determine potential anti-diabetic and 
      anti-inflammatory bioactive hits from Coriaria intermedia Matsum. stem and 
      Dracontomelon dao (Blanco) Merr. & Rolfe bark. A bioassay-guided fractionation 
      framework was used to generate bioactive fractions from C. intermedia stem and D. 
      dao bark. Subsequently, dereplication through ultra-high performance liquid 
      chromatography-tandem mass spectrometry (UHPLC-MS/MS) and database searching was 
      performed to putatively identify the components of one bioactive fraction from 
      each plant. Seven compounds were putatively identified from the C. intermedia 
      stem active fraction, and six of these compounds were putatively identified from 
      this plant for the first time. Nine compounds were putatively identified from the 
      D. dao bark active fraction, and seven of these compounds were putatively 
      identified from this plant for the first time. One putative compound from the C. 
      intermedia stem active fraction (corilagin) has been previously reported to have 
      inhibitory activity against both alpha-glucosidase and 15-lipoxygenase-1. It is 
      suggested that further studies on the potential of corilagin as an anti-diabetic 
      and anti-inflammatory treatment should be pursued based on its several beneficial 
      pharmacological activities and its low reported toxicity.
CI  - Copyright (c) 2024 Fabian, Astorga, Atis, Pilapil and Hernandez.
FAU - Fabian, Mavis Colleen Porciuncula
AU  - Fabian MCP
AD  - Bioorganic and Natural Products Laboratory, Institute of Chemistry, University of 
      the Philippines Diliman, Quezon City, Philippines.
FAU - Astorga, Rezzaira Marie Neduelan
AU  - Astorga RMN
AD  - Bioorganic and Natural Products Laboratory, Institute of Chemistry, University of 
      the Philippines Diliman, Quezon City, Philippines.
FAU - Atis, Arnelson Arwin Gray
AU  - Atis AAG
AD  - Bioorganic and Natural Products Laboratory, Institute of Chemistry, University of 
      the Philippines Diliman, Quezon City, Philippines.
FAU - Pilapil, Luis Agustin Elido
AU  - Pilapil LAE
AD  - Bioorganic and Natural Products Laboratory, Institute of Chemistry, University of 
      the Philippines Diliman, Quezon City, Philippines.
FAU - Hernandez, Christine Chichioco
AU  - Hernandez CC
AD  - Bioorganic and Natural Products Laboratory, Institute of Chemistry, University of 
      the Philippines Diliman, Quezon City, Philippines.
LA  - eng
SI  - figshare/10.6084/m9.figshare.25272313.v1
PT  - Journal Article
DEP - 20240308
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10957545
OTO - NOTNLM
OT  - 15-lipoxygenase-1
OT  - LC-MS/MS
OT  - anti-diabetic
OT  - anti-inflammation
OT  - dereplication
OT  - enzyme inhibition
OT  - terrestrial plants
OT  - alpha-glucosidase
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/25 06:42
MHDA- 2024/03/25 06:43
PMCR- 2024/03/08
CRDT- 2024/03/25 04:15
PHST- 2023/12/05 00:00 [received]
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/03/25 06:42 [pubmed]
PHST- 2024/03/25 04:15 [entrez]
PHST- 2024/03/08 00:00 [pmc-release]
AID - 1349725 [pii]
AID - 10.3389/fphar.2024.1349725 [doi]
PST - epublish
SO  - Front Pharmacol. 2024 Mar 8;15:1349725. doi: 10.3389/fphar.2024.1349725. 
      eCollection 2024.